Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesSTU:49J -0.73%17 Days Payable is 66.16 as of Mar. 2026, which is 47% above its 10-year median of 45.11. GuruFocus rates STU:49J with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Caris Life Sciences ranks worse than 68.38% on this metric.
The historical rank and industry rank for Caris Life Sciences's Days Payable or its related term are showing as below:
STU:49J'
s Days Payable Range Over the Past 10 Years
Min: 42.58 Med: 45.11 Max: 55.77
Current: 49.11
During the past 4 years, Caris Life Sciences's highest Days Payable was 55.77. The lowest was 42.58. And the median was 45.11.
STU:49J's Days Payable is ranked worse than 68.38% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:49J: 49.11
Caris Life Sciences's Days Payable
increased
from Mar. 2025 (37.81) to Mar. 2026 (66.16).
It may suggest that Caris Life Sciencesdelayed paying its suppliers.
Caris Life Sciences Days Payable Related Terms
Caris Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:49J vs DNTH, MANE, TNGX: Days Payable Comparison
For the Biotechnology subindustry, Caris Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Caris Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (STU:49J) has a Days Payable of 66.16 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Caris Life Sciences and its competitors. This is 47% above median its historical median of 45.11. Over the past decade, Caris Life Sciences' Days Payable has ranged from 42.58 to 55.77. According to the industry distribution chart, Caris Life Sciences ranks #480 out of 702 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Caris Life Sciences' Days Payable too high?
Caris Life Sciences' current Days Payable of 66.16 is 47% above median its 10-year median of 45.11. Over the past 10 years, this metric has ranged from a low of 42.58 to a high of 55.77. The Biotechnology industry median Days Payable is 113.10. Caris Life Sciences' value of 66.16 is 41.5% below this industry median. Based on the distribution chart, Caris Life Sciences ranks #480 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caris Life Sciences has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Days Payable compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #480 out of 702 companies for Days Payable. This places Caris Life Sciences in the lower half of its industry. The industry median Days Payable is 113.10. Caris Life Sciences' value of 66.16 is 41.5% below this benchmark. Historically, Caris Life Sciences' own Days Payable has ranged from 42.58 to 55.77 over the past decade. While the company's 10-year median is 45.11 vs. the industry median of 113.10, Caris Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current Days Payable of 66.16 is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Caris Life Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current Days Payable is 66.16, which is 47% above median its own 10-year median of 45.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (STU:49J) has a current Days Payable of 66.16. The current Days Payable is 66.16, which is 47% above median its 10-year median of 45.11 and 41.5% below the Biotechnology industry median of 113.10. Caris Life Sciences' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Caris Life Sciences (STU:49J), the current Days Payable is 66.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
17GF Score
Get the complete analysis for STU:49J
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:49J has been successfully added to your 
